STOCK TITAN

BrenX receives notice for $1M in additional funding

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
6-K

Rhea-AI Filing Summary

BrenX Ltd. (BRNX) received an additional $1 million funding notice from Alpha Capital Anstalt under a securities purchase agreement, subject to conditions, for up to $25 million in securities across multiple tranches. The November funding is expected to close on or about November 20, 2026. At closing, BrenX will issue 1,000 preferred shares and warrants to purchase 2,411,382 ordinary shares. The preferred shares have a stated value of $1,000 each and are convertible at $0.4147 per share; the warrants have an exercise price of $87.36 per share, are exercisable upon issuance, and expire five years from the initial exercise date.

The pricing adjusted the conversion price of previously issued preferred shares to $0.4147 under anti-dilution and ratchet provisions. Net proceeds will be used for general corporate purposes, working capital, and execution of commercial TES projects across Europe, the U.S. and the Middle East. BrenX states that, as of the funding closing, it has 3,796,155 ordinary shares and 3,913 preferred shares issued and outstanding. It also agreed to file a registration statement for resale of ordinary shares underlying the preferred shares and warrants.

Filing Explained

The November funding is still described as expected to close on or about November 20, 2026; its securities are unregistered, and BrenX has agreed to file a resale registration statement, so U.S. offers or sales require effective registration or an exemption.

Funding notice $1 million November 2026 subsequent funding notice received November 18, 2026
Preferred shares to be issued 1,000 shares At closing of the November 2026 subsequent funding
Stated value $1,000 per preferred share Preferred shares to be issued at the funding closing
Conversion price $0.4147 per share Fixed price for preferred shares converting into ordinary shares
Ordinary shares underlying warrants 2,411,382 shares Warrants to be issued at the funding closing
Warrant exercise price $87.36 per share Warrants to be issued at the funding closing
Ordinary shares issued and outstanding 3,796,155 shares As of the closing of the November 2026 subsequent funding
Preferred shares issued and outstanding 3,913 shares As of the closing of the November 2026 subsequent funding
anti-dilution and ratchet adjustment provisions technical
"under the anti-dilution and ratchet adjustment provisions"
pre-funded warrants financial
"issued pre-funded warrants and ordinary warrants"
Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.
fixed conversion price financial
"at a fixed conversion price of $0.4147 per share"
Rule 506(b) of Regulation D regulatory
"and Rule 506(b) of Regulation D promulgated thereunder"
Rule 506(b) of Regulation D is a set of rules that allows companies to raise money from investors without having to register with the government, as long as they follow certain guidelines. It lets companies offer securities to a limited number of investors, often trusted or experienced ones, making it easier and quicker to raise funds compared to traditional methods. This rule matters to investors because it provides access to private investment opportunities that are generally less regulated but still require careful consideration.
Section 4(a)(2) regulatory
"under Section 4(a)(2) of the Securities Act of 1933"
Section 4(a)(2) is a part of U.S. securities laws that allows companies to sell their stock directly to certain investors without registering the sale with regulators. This process is often used for private placements, making it easier and faster for companies to raise money from knowledgeable or institutional investors. It matters to investors because it provides an alternative way to buy shares, often with fewer disclosures and lower costs.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How much is Alpha Capital Anstalt's November 2026 funding for BRNX?

BrenX received a $1 million funding notice from Alpha Capital Anstalt on November 18, 2026, under the parties’ securities purchase agreement. The funding is expected to close on or about November 20, 2026.

What securities will BrenX (BRNX) issue under the November funding?

At closing, BrenX will issue 1,000 preferred shares and warrants to purchase 2,411,382 ordinary shares. The preferred shares have a stated value of $1,000 each and a $0.4147 conversion price. The warrants have an $87.36 exercise price, are exercisable upon issuance, and expire five years from the initial exercise date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

 

Form 6-K

 

Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
under the Securities Exchange Act of 1934

 

For the month of November 2026 (Report No. 2)

 

Commission File Number: 001-41402

 

BRENX LTD.

(Translation of registrant’s name into English)

 

13 Amal St. 4th Floor, Park Afek

Rosh Haayin, 4809249 Israel
(Address of principal executive offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F ☒        Form 40-F ☐

 

 

 

 

 

 

CONTENTS

 

As previously disclosed on a Form 6-K by BrenX Ltd., or the Company, on July 25, 2025 the Company entered into a securities purchase agreement, or the SPA, with Alpha Capital Anstalt, or Alpha, as subsequently amended, pursuant to which the Company agreed to issue and sell to Alpha, subject to certain conditions, up to an aggregate of $25 million in securities across multiple tranches, consisting of preferred shares, pre-funded warrants, and ordinary warrants.

 

Between July 2025 and September 2026, the Company completed multiple closings under the SPA, including an initial closing on July 28, 2025, pursuant to which the Company issued pre-funded warrants and ordinary warrants, and subsequent closings between September 2025 and September 2026 pursuant to which the Company issued preferred shares and accompanying ordinary warrants.

 

On November 18, 2026, the Company received an additional subsequent funding notice from Alpha in the amount of $1,000,000, or the November 2026 Subsequent Funding, pursuant to which the Company will issue (i) 1,000 preferred shares with a stated value of $1,000 per share, convertible into ordinary shares at a fixed conversion price of $0.4147 per share, and (ii) ordinary warrants to purchase 2,411,382 ordinary shares at an exercise price of $87.36 per share, which are exercisable upon issuance and will expire five years from the initial exercise date. The November 2026 Subsequent Funding is expected to close on or about November 20, 2026.

  

The net proceeds from the November 2026 Subsequent Funding will be used for general corporate purposes, working capital and execution of the Company’s commercial TES projects across Europe, the U.S. and the Middle East.

 

As a result of the pricing of the November 2026 Subsequent Funding, under the anti-dilution and ratchet adjustment provisions contained in the Company’s Amended and Restated Articles of Association, the conversion price of the preferred shares previously issued pursuant to the SPA was adjusted to $0.4147. As of the closing of the November 2026 Subsequent Funding, the Company has 3,796,155 ordinary shares issued and outstanding and 3,913 preferred shares issued and outstanding.

 

The securities referred to herein were offered pursuant to an exemption from the registration requirements under Section 4(a)(2) of the Securities Act of 1933, as amended, or the Securities Act, and Rule 506(b) of Regulation D promulgated thereunder. The securities have not been registered under the Securities Act or applicable state securities laws. Accordingly, the securities may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws. The Company has agreed to file a registration statement with the Securities and Exchange Commission, or the SEC, to register the resale of the ordinary shares underlying the preferred shares and the ordinary warrants issued pursuant to the November 2026 Subsequent Funding.

 

This Report of Foreign Private Issuer on Form 6-K is incorporated by reference into the Company’s Registration Statements on Form F-3 (File Nos. 333-273028, 333-283874, 333-289219, 333-290642, 333-292634, 333-293660, 333-294341, 333-295594, 333-296507, 333-296898, 333-297567, 333-298666 and 333-299139) and Form S-8 (File Nos. 333-272266, 333-278602, 333-284377, 333-290040, and 333-298317), filed with the Securities and Exchange Commission, to be a part thereof from the date on which this Report of Foreign Private Issuer on Form 6-K is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

 

1

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  BrenX Ltd.
   
Date: November 20, 2026 By:  /s/ Ofir Zimmerman
    Name:  Ofir Zimmerman
    Title: Chief Financial Officer

 

2

 

Keep reading